Climb Bio マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Aoife Brennan

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sep 23

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24

CEO（最高経営責任者

Aoife Brennan (48 yo)

no data

在職期間

Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, is CEO, President and Director at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) Dr. Brennan serves as Director of Xilio Therapeutics...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Aoife Brennan	CEO, President & Director	no data	データなし	データなし
Brett Kaplan	COO & Principal Financial Officer	less than a year	データなし	データなし
Emily Pimblett	Chief Accounting Officer	1.8yrs	データなし	0.011% $ 23.1k
Jo Palmer-Phillips	Chief Development Officer	no data	データなし	データなし
Nishi Rampal	Senior Vice President of Clinical Development	less than a year	データなし	データなし

0.3yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: CLYMの経営陣は経験豊富とはみなされません ( 0.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Aoife Brennan	CEO, President & Director	no data	データなし	データなし
Adam Rosenberg	Independent Director	4.1yrs	US$77.16k	0.26% $ 543.2k
Douglas Williams	Chair of Board	no data	データなし	データなし
Simon Tate	Independent Director	5.8yrs	US$22.52k	データなし
Andrew Levin	Director	no data	US$87.91k	0% $ 0
Stephen Thomas	Director	less than a year	データなし	0.15% $ 316.9k
Judith Dunn	Independent Director	3.8yrs	US$69.66k	0% $ 0

3.8yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: CLYMの取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

Climb Bio マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Climb Bio, Inc. Announces Board Changes

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Recent updates

Climb Bio, Inc. Announces Board Changes

Climb Bio, Inc. Present Additional Data from the Completed Pmn Trial and Share Clinical Data from A Single Patient with Minimal Change Disease (Mcd) Treated with Budoprutug

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. (NasdaqGM:ELYM) completed the acquisition of Tenet Medicines, Inc. from RA Capital Management, L.P. and others.

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics, Inc. announced that it has received $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. announced that it expects to receive $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

New major risk - Share price stability

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

New minor risk - Shareholder dilution

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc

Eliem Therapeutics, Inc. Announces the Resignation of Leone Patterson from the Board of Directors

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Price target decreased to US$6.00

Eliem Therapeutics, Inc. Provides Update on Pipeline Progress

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics, Inc. Provides ETX-810 Program Update

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Eliem Therapeutics, Inc. Announces Last Patient Completed Dosing in Phase 2A Study of ETX-810 in Patients with Lumbosacral Radicular Pain

Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from Russell 2500 Value Index

Eliem Therapeutics Reports Results from its Phase 2A Clinical Trial Investigating ETX-810 for the Treatment of Diabetic Peripheral Neuropathic Pain and Provided an Update on the Status of the ETX-155 Clinical Program in Epilepsy and Depression

Eliem Therapeutics, Inc., Annual General Meeting, May 19, 2022

Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

High number of new directors

High number of new and inexperienced directors

Eliem Therapeutics, Inc. has completed an IPO in the amount of $80 million.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14